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Abstract: Lethal toxin (LT) of Bacillus anthracis reduces the production of a number of 
inflammatory mediators, including transcription factors, chemokines and cytokines in 
various human cell lines, leading to down-regulation of the host inflammatory response. 
Previously we showed that the reduction of interleukin-8 (IL-8) is a sensitive marker of 
LT-mediated intoxication in human neutrophil-like NB-4 cells and that IL-8 levels are 
restored to normality when therapeutic monoclonal antibodies (mAb) with toxin-neutralising 
(TN) activity are added. We used this information to develop cell-based assays that 
examine the effects of TN therapeutic mAbs designed to treat LT intoxication and here we 
extend these findings. We present an in vitro assay based on human endothelial cell line 
HUVEC jr2, which measures the TN activity of therapeutic anti-LT mAbs using IL-8 as a 
marker for intoxication. HUVEC jr2 cells have the advantage over NB-4 cells that they are 
adherent, do not require a differentiation step and can be used in a microtitre plate format 
and therefore can facilitate high throughput analysis. This human cell-based assay provides 
a valid alternative to the mouse macrophage assay as it is a more biologically relevant 
model of the effects of toxin-neutralising antibodies in human infection. 
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1. Introduction 
Bacillus anthracis is a spore-forming bacterium, which occurs naturally in soils throughout the 
world and causes the disease anthrax. B. anthracis produces two binary toxins; edema toxin (ET) and 
lethal toxin (LT). ET is composed of protective antigen (PA) and edema factor (EF) whereas LT 
comprises PA and lethal factor (LF) [1,2]. PA binds to cell surface receptors and following cleavage 
by furin, polymerises into a heptameric structure that can bind EF and LF and promote their entry into 
the cell. EF is a calmodulin-dependent adenylate cyclase that increases intracellular cAMP, culminating 
in edema [3]. LF is a zinc metalloprotease that cleaves the amino terminus of the mitogen-activated 
protein kinase (MAPK) kinases, preventing binding to downstream mitogen activated protein kinases 
such as extracellular regulated kinase (ERK) or p38, leading to the complete inhibition of the MAP 
kinase signalling pathway and, ultimately, cell cycle arrest and cell death [4–6]. 
Inhalational anthrax is a potent bioterrorism threat because the anthrax spores are stable, relatively 
easy to aerosolize and disperse and have the potential to infect a large number of people. In addition 
the early symptoms of anthrax disease are frequently non-specific and diagnosis of anthrax is difficult 
until the disease progresses to the later stages. The result is that the fatality rate for inhalational anthrax 
is estimated to be between 45% and 90%, even after the use of aggressive antibiotic treatment. 
Post-exposure vaccination is unlikely to be protective because of the delay between exposure to 
anthrax and development of immunity. Recently, several therapeutic antibody preparations have been 
developed with the aim to treat inhalational anthrax disease. These include human or humanised 
monoclonal antibodies (mAbs) and human polyclonal antibodies which react primarily with PA, but 
also EF and LF [7,8]. Blocking the effects of the toxins is central for host protection against anthrax 
and there is significant evidence that protection is effected by anti-toxin antibody responses [9,10]. 
For the evaluation of therapeutic antibody preparations it is essential to determine the capacity of 
the antibody preparations to neutralise anthrax toxins. In vitro toxin neutralisation (TN) assays based 
on murine macrophage cell lines J774A.1 and RAW264.7 are frequently used and cell survival is 
determined following exposure to LT or to a mixture of LT and an antibody of choice [11–13]. A CHO 
cell-based assay has also been used to assess anti-PA therapeutic monoclonal antibody levels by 
measuring reduction in ET-induced cAMP levels [14].  
The murine macrophage cell lines used at present in LT assays are killed by the toxin whereas most 
human cells are resistant and hence can be used to model the in vivo effects of the toxin during human 
infection. Previously, we used the human neutrophil-like cell line NB-4 to study effects of LT 
exposure [15,16]. Cell death was not observed, however intoxicated NB-4 cells produced less mRNA 
of pro-inflammatory cytokines and transcription factors as well as lower levels of constitutively 
expressed proteins that are essential for cellular homoeostasis such as actin-related protein, ATP 
synthase β chain and high-mobility group box chromosomal protein 1 (HMGB1) [15,16]. These genes, 
with the exception of HMGB1, have been identified previously as markers for LT mediated toxicity in 
various human immune cells [15,17–22]. Reductions in mRNA and protein levels of pro-inflammatory 
cytokines such as IL-8 in NB-4 cells provided us with relevant, highly significant and sensitive 
biological markers for LT intoxication [15]. Indeed neutralisation of LT by an anti-LF monoclonal 
antibody restored IL-8 levels in cell culture supernatants [15]. However, this cell type is not easily 
adapted to a microtitre plate format, often used for routine testing: cells are non-adherent and require a Toxins 2012, 4  30 
 
 
time-consuming differentiation step. The aim of this study was to develop a high throughput assay to 
detect TN activity of anti-PA and anti-LF antibody preparations. For this purpose we replaced the  
NB-4 cells with endothelial cells. This cell type is adherent and does not require differentiation, 
making it suitable for adaptation to a microtitre plate format.  
Here we report on a TN assay that measures the activity of LT on the human endothelial cell  
line HUVEC jr2. We show that IL-8 and IL-6 production are depressed following LT exposure and 
restored to normality when toxin neutralising mAbs are added to the cells. 
2. Materials and Methods 
2.1. Anthrax Lethal Toxin 
Recombinant anthrax toxin PA and LF were obtained from List Biological Laboratories (Campbell, 
CA, USA). Antigens were snap frozen in liquid nitrogen and stored at −70 °C in 10 µL aliquots at a 
concentration of 1 mg/mL. 
2.2. Antibody Preparations 
The relevant characteristics of antibody preparations used in this study are given in Table 1. 
Table 1. Toxin-neutralising (TN) monoclonal antibodies used in this study. 
ID (Specificity)  Source  Species  TN activity [Reference] 
IQNLF (anti-LF)  IQ Therapeutics,  
The Netherlands 
Human  50% at 15 ng/mL [9] 
IQNPA (anti-PA)    50% at 50 ng/mL [9] 
IQNLF and IQNPA     >50% at 35 ng/mL [9] 
9A11 (anti-LF) 
 
Duke University,  
North Carolina, USA 
Mouse  
 
50% at 200 ng/mL [10] 
2.3. Cell Culture 
Endothelial cells were derived from a pooled stock of HUVEC jr2 cells [23]. Cells from a single 
working cell bank were used between passage 2 and passage 13 and were seeded at 0.8 × 10
6 cells per 
75 cm
2 flask and maintained in EGM-2 medium (Lonza, Slough, UK). Neutrophil-like NB-4 cells were 
derived from the promyelotic leukaemia cell line NB-4 and differentiated by exposure to 9-cis-retinoic 
acid, Vitamin D3 and granulocyte colony stimulating factor [24]. NB-4 cells were maintained in 
RPMI-1640 supplemented with 10% foetal bovine serum (FBS) and 1% L-glutamine (all from   
Sigma-Aldrich, Dorset, UK). Cells were maintained in a 95% humidified atmosphere containing 5% CO2. 
2.4. Analysis of Gene Expression in HUVEC jr2 Cells 
HUVEC jr2 cells were exposed to 40 nM LT (40 nM PA and 11 nM LF) for 2 and 4 h in line with 
previous gene expression analysis in NB-4 cells [15,16]. Untreated cells or cells treated with LF or PA 
were used as controls. Total RNA was extracted from cells (Qiagen RNeasy kit, Crawley, UK) after 
treatment and any contaminating DNA was removed by Dnase treatment (Applied Biosystems, 
Warrington, UK). cDNA was generated using Superscript II Rtase (Invitrogen, Paisley, UK) using Toxins 2012, 4  31 
 
 
random primers (Promega), following the manufacturer’s instructions. All gene expression primers and 
the universal PCR mastermix were from Applied Biosystems and used according to the manufacturer’s 
guidelines. β-actin was used as an endogenous control. Fifty nanograms of cDNA were added per 
reaction and RT PCRs were performed on an Applied Biosystems 7500 Fast instrument under standard 
cycling conditions. Quantification was performed using the comparative Ct
 method where Ct value 
was defined as threshold cycle of PCR at which amplified product was detected and normalised to the 
Ct value of housekeeping gene β-actin. Data are shown as fold change in expression relative to the 
expression level of specific mRNA in untreated cells at a given time point, which have an arbitrary 
value of 1. The results represent data combined from two separate cell experiments, with PCRs 
performed twice and using duplicate or triplicate wells. 
2.5. TN Assay Based on HUVEC jr2 Cells 
After passaging, rinsing with HEPES-buffered saline solution (Lonza) and trypsinization with 
Trypsin-EDTA (Lonza), HUVEC jr2 cells were resuspended in EGM-2 medium to 0.5 × 10
5 cells per 
ml and 10
5 cells were added per well into a 24 well plate and were incubated for 24 h at 37 °C in 5% 
CO2 for cells to attach and form a monolayer. After 24 h the spent culture medium was removed from 
the wells and replaced with fresh EGM-2 only (untreated control well) or EGM-2 containing LT and in 
some cases 1 µg/mL lipopolysaccharide (LPS) from Escherichia coli (Sigma). LT concentrations 
ranged from 10 nM PA, 1 nM LF to 0.2 nM PA, 0.02 nM LF with the highest concentration used in 
development of NB-4 based TN assay [15]. LT-specific antibody diluted to 100 µg per ml in sterile 
PBS was added at concentrations between 50 and 1000 ng/mL to appropriate wells. The cells were 
then incubated for a further 24 h and culture supernatant was removed to be assayed for IL-8 by 
ELISA. Human IgG1a (Sigma) was used as a negative control for human mAb preparations. Human 
and mouse mAbs (500 ng/mL) were added to untreated cells to verify absence of non-specific 
stimulation of IL-8 production. 
2.6. Cell Viability Assay 
A non-radioactive cell proliferation assay which measures colour change due to conversion of 
formazan to MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-dipheyltetrazolium bromide) was used as a marker 
for the number of live cells per well according to the manufacturer’s protocol (Promega, Southampton, 
UK). Absorbance readings were compared to untreated control to provide an estimate of cytotoxicity. 
2.7. IL-6 and IL-8 ELISA 
Culture medium was assayed for the presence of IL-6 and IL-8 protein using human IL-6 and IL-8 
capture ELISA kits (R and D Systems, Abingdon, UK) according to the manufacturer’s instructions. 
Cell culture supernatants were diluted 2–16-fold with reagent diluent. The data represent the mean of 
two cell experiments, assayed twice and duplicate samples for each experiment. 
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2.8. Processing and Analysis of ELISA Data 
The amount of IL-6 and IL-8 in the samples was calculated relative to the IL-6 and IL-8 standard by 
parallel line assay. The calculations were performed using the current version of Combistats statistical 
analysis program [25]. OD readings were corrected for background and were required to be within a 
range of 2.25–0.20. Only results within the linear dose range of the curve were used for the potency 
calculation. Potency values derived from the parallel line assay were converted to IL-8 content in 
pg/mL. Statistical analysis of ELISA data was carried out by the analysis of variance with   
Dunnett’s test. 
3. Results 
3.1. Lethal Toxin Rapidly Alters Gene Expression in Endothelial Cells 
Gene expression of six cytokines, three transcription factors (early growth response genes (egr) 1-3) 
and vascular cell adhesion molecule (VCAM)-1 were examined in HUVEC jr2 cells after exposure to 
LT. RT-PCR results show that the effect of LT exposure was more pronounced at 4 h than at   
2 h (Figure 1). At 4 h, significant decreases in mRNA were seen for IL-6, IL-8 and CCL20; this pattern 
concurred with previous findings in NB-4 cells by Barson et al. [15].  
Figure 1. Lethal toxin (LT) rapidly alters the expression of chemokines, cytokines and 
transcription factors in HUVEC jr2 cells after 2 and 4 h. Cells were exposed to 40 nM LT 
(40 nM PA + 11 nM LF) or left untreated. The data presented here compares the   
LT-treated cells to untreated cells at 2 and 4 h and the fold change for both 2 and 4 h 
untreated cells is 1. Data from two independent experiments are shown as relative 
expression ± SEM. *** p < 0.001; ** p < 0.01; * p < 0.05. 
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Some differences in the cellular response after exposure to LT were observed between the two cell 
types however. IL-6 mRNA could not be detected in NB-4 cells and CCL2 (monocyte chemotactic 
protein-1) gene expression was down-regulated in NB-4 cells but in endothelial cells no change was 
observed.  Egr-1  and egr-2 were down-regulated in HUVEC jr2 cells whereas egr-3 remained 
unchanged. Down-regulation of egr1 in endothelial cells after LT exposure was also reported by 
Rolando  et al. [22]. In NB-4 cells, egr 1–3 were down-regulated [15]. Levels of IL-1β mRNA 
increased after 4 h and TNF-α mRNA showed a transitory increase in expression at 2 h which had 
fallen back to normal levels by 4 h. Both genes are key mediators of the acute phase response and have 
previously been shown to be down-regulated in murine macrophages and NB-4 cells exposed to   
LT [15,26]. 
The effect of LT on the mRNA expression of vcam-1 was examined and our results show a 2-fold 
increase which is in line with findings by Warfel and D’Agnillo [27]. VCAM-1 expression is thought 
to be associated with vascular leakage which is caused by disruption of the vascular endothelium, a 
key feature of anthrax pathogenesis in clinical cases and in animals injected with LT [27–29].  
3.2. LT Reduces Cytokine Production in Endothelial Cells 
Spent culture medium from cells treated with LT was analysed for the presence of IL-6 and IL-8 
proteins. In one series of experiments the HUVEC jr2 cells were stimulated with lipopolysaccharide 
(LPS) to ensure that any changes in cytokine production following LT treatment were of sufficient 
magnitude. LPS induces cytokine production via activation of Toll-like receptors in a similar manner 
to B. anthracis [30].  
Results showed that for HUVEC jr2 cells treatment with LT ranging from 10 nM PA and 1 nM LF 
to 0.2 nM PA and 0.02 nM LF reduced the level of IL-6 and IL-8 irrespective of LPS treatment. In 
unstimulated cells the production of IL-6 was reduced significantly except when treated with the 
lowest concentration (Figure 2A). In LPS-stimulated cells, LT caused reductions of IL-6 of between 
1.2 to 5.5-fold however this reduction was not significant at the lowest LT concentration (Figure 2B). 
Levels of IL-8 protein were similarly reduced by LT treatment with LPS-stimulated cells with 
decreases of 1.3 to 2-fold for all but the lowest concentration. In unstimulated cells the reduction was 
between 1.25 to 3-fold. The lowest concentration of 0.2 nM PA and 0.02 nM LF reduced IL-8 by a 
significant degree for the unstimulated cells only (Figure 2A). Both the unstimulated HUVEC jr2 cells 
and those stimulated with LPS gave a clearly defined dose response with the concentrations of LT used 
for both IL-6 and IL-8 and statistical analysis revealed that the decline in IL-6 and IL-8 was 
significant. The decrease in IL-8 production by LT-treated cells was not likely to be due to a decrease 
in cell viability as it ranged from 93% for LT10 to 97% for LT0.2, compared to the untreated control. 
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Figure 2. LT decreases protein levels of IL-6 and IL-8 in unstimulated (A) and   
LPS-stimulated (B) HUVEC jr2 cells. Cells were treated with concentrations of LT   
(LT10–10 nM PA and 1.0 nM LF, LT5–5 nM PA and 0.5 nM LF, LT2.5–2.5 nM PA and 
0.25 nM LF, LT1–1 nM PA and 0.1 nM LF, LT0.2–0.2 nM PA and 0.02 nM LF) and/or 
LPS (1 μg/mL) for 24 h and conditioned medium was collected and analysed by ELISA. 
Data shown as mean ± SEM (n = 4). *** p < 0.001; ** p < 0.01; * p < 0.05 compared to 
untreated control (unstimulated or LPS-stimulated as appropriate). 
     
3.3. Application of HUVEC jr2 Cells in Toxin Neutralisation Assay 
We have demonstrated previously that the production of IL-8 by NB-4 cells is a very sensitive 
marker of LT-mediated intoxication. Levels of IL-8 are depressed in the presence of LT but are 
restored to normality when toxin neutralising mAbs are added to the cells [15]. This formed the basis 
of a TN assay to confirm the potency of both anti-PA and anti-LF mAbs. However, the use of NB-4 
cells in this assay has two disadvantages. NB-4 cells are not adherent and thus are not suitable for 
culture in a microtitre plate environment and NB-4 cells require differentiation to acquire a neutrophil-like 
phenotype. Thus a TN assay based on endothelial cells should be easier to perform and allow for 
multiple samples to be tested concurrently. 
A modified assay procedure was developed for the endothelial cell line HUVEC jr2. After exposure 
to LT, this cell line showed a more marked decrease in the production of IL-8 compared to IL-6 
(Figure 2). Therefore we chose to use IL-8 as a marker of LT intoxication in HUVEC jr2 cells as the 
basis of the TN assay. 
For the assay, 10
5 cells were seeded into each well of a 24-well plate. LT and the anti-LF mAb 
IQNLF were added and plates were incubated at 37 °C for 24 h. The spent culture medium was 
collected and IL-8 production was measured by ELISA. Levels of IL-8 protein were reduced when LT 
was added and addition of IQNLF resulted in a restoration of IL-8 production to normal levels. This 
effect was seen in both LPS-stimulated and unstimulated cells (Figure 3) and in both cases the decline 
and restoration of IL-8 following treatments was statistically significant. In unstimulated cells treated 
with LT, restoration of IL-8 showed a good dose response over a range of mAb concentration of  
30–500 ng/mL thus removing the requirement for prior stimulation with LPS in the TN assay (see  
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also 3.2). To rule out the possibility that addition of the mAb into the TN assay could non-specifically 
induce changes in IL-8 we added IQNLF at 500 ng/mL and our results showed that there was no 
significant difference in IL-8 production compared to the control. 
Figure 3. Restoration of IL-8 protein production by anti-LF mAb IQNLF in 
(A) unstimulated HUVEC jr2 cells and (B) LPS stimulated HUVEC jr2 cells exposed to 
LT. UT or LPS-control, LT5–5 nM PA and 0.5 nM LF, LT2.5–2.5 nM PA and 0.25 nM 
LF. Antibody concentrations were from 30 to 500 ng/mL for IQNLF. Data shown as   
mean ± SEM (n = 4). *** p < 0.001 compared to LT treated cells.  
     
3.4. TN Antibodies Restore IL-8 Production in LT-Treated HUVEC jr2 Cells  
Once we had established the suitability of HUVEC jr2 cells for use in a microtitre plate format, we 
examined the ability of other TN mAbs to restore levels of IL-8 production in unstimulated LT-treated 
cells. We observed that the anti-PA mAb IQNPA was able to restore IL-8 production, at concentrations 
of 250 to 1000 ng of mAb per mL, although IL-8 levels were not restored to 100% compared to the 
untreated control (Figure 4A). Anti-LF mAb 9A11 completely restored IL-8 production in HUVEC jr2 
cells at concentrations of 250, 500 and 1000 ng/mL (Figure 4B). HUVEC jr2 cells did not produce 
higher levels of IL-8 following exposure to 500 ng/mL of mAbs IQNPA or 9A11 (results not shown).  
When anti-PA mAb IQNPA and anti-LF mAb IQNLF were combined for use in the TN assay  
(25 ng/mL of each) we found that their presence increased IL-8 levels significantly but that a single 
mAb did not restore IL-8 production at this concentration of 50 ng of mAb per mL. IL-8 levels were 
restored completely in the presence of 500 ng per ml of each antibody and also with the IQNLF and 
IQNPA combination (Figure 5). 
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Figure 4. Restoration of IL-8 protein production by anti-anthrax mAbs (A) IQNPA and 
(B) 9A11 in HUVEC jr2 cells exposed to LT. UT–untreated control, LT–2.5 nM PA and  
0.25 nM LF. Antibody concentrations ranged from 30 to 1000 ng/mL for IQNPA and 
9A11. Data shown as mean and SEM (n = 4). *** p < 0.001; ** p < 0.01 compared to LT 
treated cells. 
     
Figure 5. Efficacy of IQNLF and IQNPA mAbs in restoring IL-8 protein production by 
HUVEC jr2 cells exposed to LT (5 nM PA and 0.5 nM LF). * p < 0.05 for LT + 50 (25 ng 
IQNLF and 25 ng IQNPA per mL) compared to LT + 0 (no antibody treatment), # p < 0.05 
(25 ng IQNLF and 25 ng of IQNPA combined compared to 50 ng of IQNLF or IQNPA),  
*** p < 0.001 for LT + 500 (500 ng IQNLF or IQNPA per mL or 250 ng of IQNLF and  
250 ng of IQNPA per ml) compared to LT + 0. 
 
4. Discussion 
Here we demonstrate that human endothelial cells can be used in a microtitre plate format to detect 
LT mediated toxicity and TN activity of mAbs. Endothelial cells have two major advantages over  
NB-4 cells which allow the development of this application: cells are adherent, making these cells 
more suitable for culture in a microtitre plate format and cell differentiation and stimulation by LPS 
can be omitted making routine culture of this cell line simpler and less costly. Like NB-4 cells, 
HUVEC jr2 cells proved very sensitive to the effects of LT [15], which manifested itself by a decrease 
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in mRNA transcription of various cytokines (IL-6 and IL-8) and transcription factors, such as egr1, a 
master regulator of transcription. The down-regulation of egr1 by LT has been reported for other 
endothelial cell lines exposed to LT or wild-type B. anthracis [22,31]. Lower levels of egr1 lead to the 
formation of actin cables, which were associated with barrier dysfunction [22,32]. Our results indicate 
that the egr family of transcription factors is regulated differently in endothelial cells compared to 
neutrophil-like NB-4 cells. Thus it is likely that LT has cell-type specific effects which in turn affect 
different sets of genes regulated by MAP kinases [33]. The gene expression of several regulators of the 
actin cytoskeleton such as cortactin and rhophilin-2 are modulated by LT in endothelial cells [22] and 
LT also directly blocks the signalling pathways controlling actin regulators [18,19].  
Abnormal or dysregulated VCAM-1 activation is linked to vasculitis and inflammatory disorders, 
both of which are key features of anthrax pathogenesis. We examined the effect of LT on vcam1 and 
our results show a 2-fold increase in expression in line with findings by Steele et al. [34] and Warfel 
and D’Agnillo [27].  
In addition, several reports in the literature have shown conclusively that endothelial cells are a 
target for LT and their deterioration plays an important role in the progression of infection [2,17,28,31].  
IL-8 is an important mediator of inflammation which acts both as a cytokine and a chemokine by 
recruiting neutrophils to sites of infection and activating them to eliminate pathogens by phagocytosis 
and by production of oxygen radicals and nitric oxide. Previous studies have shown that LT may 
achieve lower IL-8 expression in two ways: through mRNA destabilization [17] and by preventing 
histone H3 phosphorylation at Ser 10 thus altering chromatin accessibility of IL-8 promoter to NF-κB 
in epithelial cells [35]. 
Both the anti-PA and anti-LF mAbs tested by us in the TN assay were able to neutralise LT 
effectively. Human mAbs, IQNLF and IQNPA, were shown to be potent inhibitors of LT activity. 
IQNPA specifically recognises domain IV of PA, thus impeding the binding of PA to its cell surface 
receptors. IQNLF binds to domain I of LF and may prevent interaction of LF with PA [9]. We 
examined whether these antibodies could act together when combined to inhibit LT activity in 
endothelial cells. The potency of these mAbs increased significantly when they were combined in the 
TN assay indicating a possible synergistic effect. Previously an additive effect was reported in the 
mouse macrophage assay [9], suggesting that LT and the mAbs interact differently with human 
endothelial cells than with mouse macrophages. LT activates the inflammasome of macrophages from 
several mouse and rat strains, through the NOD-like receptor protein (Nlrp) 1b, leading to rapid cell 
death as a result of capase-1 production [36,37]. This activity was found to be absent in human 
macrophages, possibly due to a different Nlrp1b type in humans [37]. As LT acts differently on mouse 
and human cell lines the TN assays based on mouse macrophages and human cells are likely to give 
different outcomes following exposure of cells to LT or to a mixture of LT and TN mAbs.  
The mouse mAb 9A11 was also demonstrated to be a potent LT-neutralising Ab. 9A11 differs in its 
mode of action from IQNLF and binds to two different epitopes within the LF zinc-binding domain 
involved in LF substrate recognition, effectively blocking enzymatic activity [38]. 
Taken together these changes induced by LT in HUVEC jr2 cells may contribute to dysfunctional 
endothelial cell stress which will lead to barrier dysfunction and vascular leakage and ultimately will 
compromise the integrity of blood vessels.  Toxins 2012, 4  38 
 
 
We conclude that the use of human endothelial cells in this in vitro TN assay model is a valid 
alternative to mouse macrophage assay and that it provides a more biologically relevant representation 
of events that characterise the interaction between LT and the human host. We accept that comparisons 
between our assay and the mouse macrophage TN assay may not be straight forward. However we 
believe that this assay will enable us to determine the counter effects of TN monoclonal antibody 
preparations on a different level, which will aid our understanding of the neutralising capabilities of 
therapeutic mAbs. 
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